{"id":862373,"date":"2025-06-20T16:08:16","date_gmt":"2025-06-20T20:08:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/"},"modified":"2025-06-20T16:08:16","modified_gmt":"2025-06-20T20:08:16","slug":"larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/","title":{"rendered":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia"},"content":{"rendered":"

\nConference call and webcast on Monday, June 23, 2025 at 8:00 am EDT
\n<\/h2>\n
\n

BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company\u2019s nomlabofusp clinical development program for the treatment of Friedreich\u2019s Ataxia on Monday, June 23, 2025 at 8:00 am EDT.<\/p>\n

\n Conference Call and Webcast Details
<\/strong>To access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link<\/a> to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or click on this link<\/a> and request a return call. Following the live event, an archived webcast will be available on the\u00a0\u201cEvents & Presentations\u201d<\/a>\u00a0page of the Larimar website.<\/p>\n

\n About\u00a0Larimar Therapeutics<\/strong>
\n
Larimar Therapeutics, Inc.\u00a0(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit:\u00a0https:\/\/larimartx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are based on Larimar\u2019s management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar\u2019s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar\u2019s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plans and other matters regarding Larimar\u2019s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n

In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar\u2019s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar\u2019s nomlabofusp development strategy; the potential impact of public health crises on Larimar\u2019s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar\u2019s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp\u2019s manufacturing process; Larimar\u2019s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar\u2019s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by\u00a0Larimar\u00a0with the\u00a0Securities and Exchange Commission\u00a0(SEC), including but not limited to Larimar\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the\u00a0SEC\u00a0and available at\u00a0www.sec.gov<\/a>. These forward-looking statements are based on a combination of facts and factors currently known by\u00a0Larimar\u00a0and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar\u2019s management\u2019s views only as of the date hereof.\u00a0Larimar\u00a0undertakes no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com<\/a>
(212) 915-2569<\/p>\n

\n Company Contact:<\/strong>
\n
Michael Celano
Chief Financial Officer
mcelano@larimartx.com<\/a>
(484) 414-2715<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company\u2019s nomlabofusp clinical development program for the treatment of Friedreich\u2019s Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or … <\/p>\n

Continue reading “Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-862373","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company\u2019s nomlabofusp clinical development program for the treatment of Friedreich\u2019s Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or … Continue reading "Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-20T20:08:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia\",\"datePublished\":\"2025-06-20T20:08:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/\"},\"wordCount\":765,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/\",\"name\":\"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2025-06-20T20:08:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk","og_description":"Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company\u2019s nomlabofusp clinical development program for the treatment of Friedreich\u2019s Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or … Continue reading \"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-20T20:08:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia","datePublished":"2025-06-20T20:08:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/"},"wordCount":765,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/","name":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==","datePublished":"2025-06-20T20:08:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ3MjA3NSM3MDAxMzI3IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-announces-regulatory-update-call-on-the-nomlabofusp-program-for-the-treatment-of-friedreichs-ataxia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich\u2019s Ataxia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=862373"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862373\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=862373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=862373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=862373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}